Transaction DateRecipientSharesTypePriceValue
10th September 2020Heek G Jan Van7,000Open or private purchase$2.97$20,790.00
31st July 2020William F Doyle896Open or private sale$76.39$68,443.65
16th June 2020Jeryl L Hilleman8,797Grant/award etc.$0.00
10th June 2020Jeryl L Hilleman2,541Grant/award etc.$0.00
26th May 2020Frederick W Ahlholm8,339Open or private sale$15.00$125,085.00
11th May 2020William F Doyle31,332Open or private sale$63.73$1,996,725.70
8th May 2020William F Doyle58,767Exercise of derivative$63.84$3,751,685.28
8th May 2020William F Doyle31,903Open or private sale$63.50$2,025,872.40
7th May 2020William F Doyle58,768Exercise of derivative$64.77$3,806,403.36
7th May 2020William F Doyle30,993Open or private sale$64.74$2,006,517.81
Minerva Neurosciences
Minerva Neurosciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. The company was founded by Rogerio Vivaldi Coelho in 2007.

Ticker: NERV
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1598646
Employees: 13
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags